ArticleBMC pulmonary medicine2026
Blood eosinophil count and clinical characteristics according to etiology in chronic obstructive pulmonary disease.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a heterogeneous condition with multiple etiologies. We evaluated whether clinical characteristics differ according to COPD etiology.
methodsPatients with infection as the sole etiology were classified as the infection-related group (COPD-I, Group I), whereas those with any smoking-related etiology were assigned to the smoking-related group (COPD-C, Group C).
resultsOf 873 patients included, 41 were classified as Group I and 832 as Group C. A significantly higher proportion of patients in Group I had a blood eosinophil count < 100 cells/µL compared to Group C (44.4% vs. 27.8%; p = 0.031). The inhaled corticosteroid (ICS) prescription rate was lower in Group I compared to Group C (25.7% vs. 41.5%; p = 0.063). Multivariable logistic regression confirmed that Group I was independently associated with a lower likelihood of ICS use (p = 0.018). In addition, Group I exhibited a significantly higher residual volume to total lung capacity ratio (48.88% vs. 43.28%; p = 0.030), indicating greater air trapping and small airway involvement.
conclusionsThese findings support the notion that infection-related COPD (COPD-I) represents a clinically distinct phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.